More good T3 news. Hopefully, in the none too distant future, there will be sufficient evidence that it is beneficial in the treatment of poor converter hypothyroid patients too.
Patients with Allan-Herndon-Dudley syndrome (AHDS), an extremely rare, X-linked disorder causing moderate to severe intellectual disability and problems with movement, show significant improvement in total triiodothyronine (T3) levels in response to treatment with the T3 analog triiodothyroacetic acid (triac), according to new research.
Cont'd in medscape.com/viewarticle/85...